Bitrobius Genetics is a UK based genetic medicines company focussed on developing cures for poorly treated genetic diseases by solving the number one problem in gene therapy: the challenge of getting the correct copy of a mutated gene to most of the cells where it is needed. By overcoming this challenge its Gentrafix™ technology will give rise to multiple therapeutic products to treat, and potentially cure, unmet medical needs in genetic diseases. Bitrobius has received seed investment from venture capital firms Science Creates Ventures (SCVC), Future Planet Capital, Synbioven and Catapult Ventures, plus significant grant funding from Innovate UK, the national innovation agency of the United Kingdom.
Bitrobius Genetics: Venture Capital Funding History
Bitrobius Genetics
Bitrobius Genetics
- Life Sciences
- Cheshire, United Kingdom
- £700k
- bitrobius.com
- Update Information
More venture news
- 26 Oct 2026

adsilicoadsilico unlocks a £10m Series A round led by PXN Ventures for virtual testing of implantable medical devices
Series ALife Sciences - 26 Oct 2026

imphatecimphatec raises a £1.5m seed round led by SynBioVen to develop customisable-dose implants for chronic conditions
SeedLife Sciences - 15 Oct 2026

OMass TherapeuticsOMass Therapeutics raises a £230m Series C round from VCs including Bain Capital to develop small molecule therapeutics with drug discovery platform
Series CLife Sciences
